ImmunityBio Inc. (IBRX) has entered into a definitive agreement granting the company exclusive U.S. rights to develop, import, and market the Tokyo-172 strain of Bacillus Calmette-Guérin (BCG) from Japan BCG Laboratory. The announcement, made over the weekend, sets the stage for Monday's trading session as investors assess the potential impact on the company's bladder cancer treatment portfolio.
The Tokyo-172 strain remains investigational in the United States and has not received approval from the U.S. Food and Drug Administration (FDA). ImmunityBio plans to engage with the FDA to outline its regulatory pathway, including the submission of a Biologics License Application (BLA). The company emphasized that it will serve as the sole applicant for U.S. marketing authorization.
Market Reaction and Trading Context
ImmunityBio shares closed Friday at $7.97, down 2.2% on the day and roughly 6.3% lower for the week. The decline came amid a broader selloff in risk assets, with the Nasdaq Composite falling 1.54% and the SPDR S&P Biotech ETF (XBI) losing 3.08%. Friday's trading volume on ImmunityBio was 11.35 million shares, lighter than the previous week when activity spiked around the company's earnings report.
With U.S. stock markets closed over the weekend, Monday will provide the first opportunity for traders to react to the BCG supply deal. The news adds a new dimension to the company's growth narrative, which already includes its approved drug Anktiva.
Clinical and Competitive Landscape
ImmunityBio's lead product, Anktiva, is already approved in the U.S. for use in combination with BCG for certain patients with non-muscle invasive bladder cancer (NMIBC) that is BCG-unresponsive. BCG, originally developed as a tuberculosis vaccine, is instilled into the bladder to stimulate the immune system against tumors. The new agreement with Japan BCG Laboratory could provide a second potential U.S. supply source for BCG, addressing a chronic shortage that has persisted for over a decade, according to ImmunityBio CEO Richard Adcock.
The company cited results from the SWOG S1602 Phase III trial, which demonstrated non-inferiority of the Tokyo-172 BCG strain compared to TICE BCG in BCG-naive patients with high-grade NMIBC. Founder and executive chairman Patrick Soon-Shiong called the study "rigorous, publicly funded science."
Competition in the NMIBC space includes Merck & Co.'s Keytruda, approved for BCG-unresponsive high-risk NMIBC, and Ferring's Adstiladrin, also indicated for high-grade BCG-unresponsive disease. ImmunityBio's strategy differs by combining Anktiva with BCG rather than replacing it.
Financial Position and Regulatory Hurdles
ImmunityBio's first-quarter product revenue surged 168% year-over-year to $44.2 million, driven by strong demand for Anktiva. However, the company reported a net loss attributable to common stockholders of $632.8 million, largely due to non-cash fair-value changes in warrants, derivatives, and a related-party convertible note. As of the end of the quarter, the company held $380.9 million in cash and marketable securities.
The company faces ongoing regulatory scrutiny. In March, the FDA issued a warning letter regarding an Anktiva television advertisement and podcast that the agency deemed false or misleading, misbranding the drug and implying it could cure or prevent all cancer. ImmunityBio has been instructed to address the violations. Additionally, the company disclosed in its 10-Q filing that it expects to require additional funding for future operations, including commercialization and development activities.
Piper Sandler analyst Edward Tenthoff maintained his Anktiva sales estimates following the FDA warning letter, expressing confidence that ImmunityBio can meet the agency's requirements without revising his revenue projections.
Outlook
Investors will be watching Monday's trading closely to gauge whether the BCG supply deal represents a meaningful strategic move or merely another step in a lengthy regulatory process. Key catalysts ahead include updates on FDA timing for the Tokyo-172 strain and continued commercial traction for Anktiva. Broader market sentiment, including interest rate concerns and risk appetite, will also influence the stock's direction, particularly after Friday's selloff in biotech and technology shares.
